Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma

被引:61
作者
Dong, Qiong-Zhu
Zhang, Xiao-Fei
Zhao, Yue
Jia, Hu-Liang
Zhou, Hai-Jun
Dai, Chun
Sun, Hai-Jing
Qin, Yi
Zhang, Wei-De
Ren, Ning
Ye, Qing-Hai [1 ]
Qin, Lun-Xiu [1 ]
机构
[1] Fudan Univ, Liver Canc Inst, Shanghai 200032, Peoples R China
关键词
TUMOR-GROWTH; GENE-EXPRESSION; MARKER; SUSCEPTIBILITY; REGION; IDENTIFICATION; RECURRENCE; EFFICACY; THERAPY; CELLS;
D O I
10.1002/hep.26103
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Osteopontin (OPN) plays a crucial role in hepatocellular carcinoma (HCC) metastasis. However, little is known about the impact of OPN polymorphisms on cancer progression. In this study, we first identified the single nucleotide polymorphisms (SNPs) in the OPN promoter region by direct sequencing in 30 HCCs, and then evaluated the prognostic values of the selected ones in two large cohorts of 826 HCC patients. The identified SNPs were functionally analyzed using in vitro and in vivo assays and their correlations with OPN levels were also evaluated. Only SNP at locus -443 and their related haplotypes (Ht2: -1748A/-616G/-443T/-155* [*indicates base deletion]; Ht3: -1748A/-616G/-443C/-155*) were significantly associated with overall survival (OS) and time to recurrence (TTR). The patients with the -443TT/TC genotype or Ht2 had a shorter OS and TTR compared with those with -443CC genotype or Ht3. This was further confirmed in the validation cohort. Moreover, this correlation remained significant in patients with small HCCs (5 cm). Multivariate analyses indicated that the prognostic performance of the -443 genotypes (OS, P = 0.031; TTR, P = 0.005) and their related haplotypes (OS, P = 0.002; TTR, P = 0.001) was independent of other clinicopathological factors. The Ht2 and -443TT genotype could significantly increase the promoter transcriptional activity and expression level of OPN compared with the Ht3 or -443CC genotype, and lead to an obvious increase in both in vitro invasion and in vivo tumor growth and lung metastasis of HCC cells (P < 0.05). Conclusion: The genetic variation at locus -443 of the OPN promoter plays important roles in the regulation of OPN expression and cancer progression of HCCs, which is a novel determinant and target for HCC metastasis and prognosis. (HEPATOLOGY 2013)
引用
收藏
页码:1024 / 1034
页数:11
相关论文
共 35 条
  • [1] Haploview: analysis and visualization of LD and haplotype maps
    Barrett, JC
    Fry, B
    Maller, J
    Daly, MJ
    [J]. BIOINFORMATICS, 2005, 21 (02) : 263 - 265
  • [2] A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci
    Bei, Jin-Xin
    Li, Yi
    Jia, Wei-Hua
    Feng, Bing-Jian
    Zhou, Gangqiao
    Chen, Li-Zhen
    Feng, Qi-Sheng
    Low, Hui-Qi
    Zhang, Hongxing
    He, Fuchu
    Tai, E. Shyong
    Kang, Tiebang
    Liu, Edison T.
    Liu, Jianjun
    Zeng, Yi-Xin
    [J]. NATURE GENETICS, 2010, 42 (07) : 599 - U173
  • [3] Serial plasma osteopontin levels have prognostic value in metastatic breast cancer
    Bramwell, Vivien H. C.
    Doig, Gordon S.
    Tuck, Alan B.
    Wilson, Sylvia M.
    Tonkin, Katia S.
    Tomiak, Anna
    Perera, Francisco
    Vandenberg, Theodore A.
    Chambers, Ann F.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (11) : 3337 - 3343
  • [4] The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis
    Chiu, Yu-Wei
    Tu, Hsi-Feng
    Wang, I-Kai
    Wu, Cheng-Hsien
    Chang, Kuo-Wei
    Liu, Tsung-Yun
    Kao, Shou-Yen
    [J]. ORAL ONCOLOGY, 2010, 46 (04) : 302 - 306
  • [5] Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus
    D'Alfonso, S
    Barizzone, N
    Giordano, M
    Chiocchetti, A
    Magnani, C
    Castelli, L
    Indelicato, M
    Giacopelli, F
    Marchini, M
    Scorza, R
    Danieli, MG
    Cappelli, M
    Migliaresi, S
    Bighardo, B
    Sabbadini, MG
    Baldissera, E
    Galeazzi, A
    Sebastiani, GD
    Minisola, G
    Ravazzolo, R
    Dianzani, U
    Momigliano-Richiardi, P
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 539 - 547
  • [6] The regulation and role of osteopontin in malignant transformation and cancer
    El-Tanani, Mohamed K.
    Campbell, Frederick Charles
    Kurisetty, Vittal
    Jin, Dachuan
    McCann, Mella
    Rudland, Philip S.
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (06) : 463 - 474
  • [7] Hepatocellular carcinoma
    Forner, Alejandro
    Llovet, Josep M.
    Bruix, Jordi
    [J]. LANCET, 2012, 379 (9822) : 1245 - 1255
  • [8] Polymorphisms in the osteopontin promoter affect its transcriptional activity
    Giacopelli, F
    Marciano, R
    Pistorio, A
    Catarsi, P
    Canini, S
    Karsenty, G
    Ravazzolo, R
    [J]. PHYSIOLOGICAL GENOMICS, 2004, 20 (01) : 87 - 96
  • [9] SPPI promoter polymorphisms:: Identification of the first modifier gene for pseudoxanthoma elasticum
    Hendig, Doris
    Arndt, Marius
    Szliska, Christiane
    Kleesiek, Knut
    Goetting, Christian
    [J]. CLINICAL CHEMISTRY, 2007, 53 (05) : 829 - 836
  • [10] Increased expression of osteopontin contributes to the progression of prostate cancer
    Khodavirdi, AC
    Song, ZG
    Yang, SX
    Zhong, C
    Wang, SY
    Wu, H
    Pritchard, C
    Nelson, PS
    Roy-Burman, P
    [J]. CANCER RESEARCH, 2006, 66 (02) : 883 - 888